Delfi Diagnostics outlined a 2026 roadmap of multiple pivotal data readouts for its FirstLook Lung liquid biopsy, aiming to support regulatory submission and commercial reimbursement. CEO Susan Tousi told investors that topline results from prospective trials—including 4‑In‑The‑Lung‑Run and the US registrational CASCADE‑LUNG—will underpin planned FDA filings and payor engagements. Delfi reported prior case‑control sensitivity of about 80 percent overall and 71 percent in stage I disease. The company said CASCADE‑LUNG (a 12,000‑patient US registrational study) will support a premarket approval submission expected after 2026 readouts, with the firm targeting guideline inclusion and payor coverage thereafter. Delfi emphasized clinical‑utility and large prospective datasets as critical for payer conversations. Market observers view Delfi’s strategy as emblematic of next‑gen cfDNA screening companies: generate robust prospective evidence to move from laboratory‑developed tests to regulated, reimbursed diagnostics.